Free Trial
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$29.21 +0.23 (+0.79%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Key Stats

Today's Range
$28.84
$29.39
50-Day Range
$26.13
$30.46
52-Week Range
$25.56
$36.45
Volume
1.24 million shs
Average Volume
1.56 million shs
Market Capitalization
$4.82 billion
P/E Ratio
14.04
Dividend Yield
N/A
Price Target
$41.08
Consensus Rating
Moderate Buy

Company Overview

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

ALKS MarketRank™: 

Alkermes scored higher than 94% of companies evaluated by MarketBeat, and ranked 84th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is 14.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is 14.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.83.

  • Price to Earnings Growth Ratio

    Alkermes has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Alkermes' valuation and earnings.
  • Percentage of Shares Shorted

    8.76% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 9.94%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.76% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 9.94%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Alkermes has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Alkermes this week, compared to 8 articles on an average week.
  • Search Interest

    Only 8 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $210,143.00 in company stock.

  • Percentage Held by Insiders

    Only 4.40% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALKS Stock News Headlines

Zacks Research Predicts Alkermes' Q3 Earnings (NASDAQ:ALKS)
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $41.08
Piper Sandler Keeps Their Buy Rating on Alkermes (ALKS)
Alkermes Earnings Call: Strong Growth and Promising Trials
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $28.76 on January 1st, 2025. Since then, ALKS shares have increased by 1.7% and is now trading at $29.25.

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Tuesday, July, 29th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.10. Alkermes's revenue for the quarter was down 2.1% on a year-over-year basis.
Read the conference call transcript
.

Alkermes' Board of Directors initiated a share buyback plan on Thursday, February 15th 2024, which permits the company to repurchase $400,000,000 in shares, according to EventVestor. This means that the company could buy up to 8.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

The following companies are subsidiaries of Alkermes: Rodin Therapeutics.

Alkermes' top institutional shareholders include State Street Corp (4.97%), JPMorgan Chase & Co. (2.93%), Geode Capital Management LLC (2.44%) and American Century Companies Inc. (2.22%). Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
7/29/2025
Today
8/27/2025
Next Earnings (Estimated)
10/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CIK
1520262
Employees
1,800
Year Founded
1987

Price Target and Rating

High Price Target
$52.00
Low Price Target
$26.00
Potential Upside/Downside
+40.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.08
Trailing P/E Ratio
14.06
Forward P/E Ratio
22.33
P/E Growth
1.67
Net Income
$367.07 million
Net Margins
23.15%
Pretax Margin
27.27%
Return on Equity
24.86%
Return on Assets
17.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.23
Quick Ratio
2.85

Sales & Book Value

Annual Sales
$1.56 billion
Price / Sales
3.10
Cash Flow
$2.68 per share
Price / Cash Flow
10.93
Book Value
$9.84 per share
Price / Book
2.97

Miscellaneous

Outstanding Shares
165,080,000
Free Float
157,815,000
Market Cap
$4.83 billion
Optionable
Optionable
Beta
0.47

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners